DrugPatentWatch Database Preview
Patent: 10,293,030
Summary for Patent: 10,293,030
| Title: | Lyophilised pharmaceutical formulation and its use |
| Abstract: | A pharmaceutical formulation in a lyophilised form, which comprises pharmacologically effective amount of interferon beta-1a as an active ingredient, disaccharides as a bulking agent and a non-ionic surfactant. After reconstitution, the composition can be administered intravenously. |
| Inventor(s): | Jalkanen; Markku (Piispanristi, FI), Maksimow; Mikael (Turku, FI), Piippo; Ilse (Parainen, FI) |
| Assignee: | Faron Pharmaceuticals Oy (Turku, FI) |
| Application Number: | 15/355,691 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,293,030
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Serono Inc | REBIF | interferon beta-1a | SYRINGE | 103780 | 002 | 2002-03-07 | Start Trial | Faron Pharmaceuticals Oy (Turku, FI) | 2036-02-29 | RX | search | |
| Serono Inc | REBIF | interferon beta-1a | SYRINGE | 103780 | 001 | 2002-03-07 | Start Trial | Faron Pharmaceuticals Oy (Turku, FI) | 2036-02-29 | RX | search | |
| Biogen | AVONEX | interferon beta-1a | VIAL | 103628 | 001 | 1996-05-17 | Start Trial | Faron Pharmaceuticals Oy (Turku, FI) | 2036-02-29 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,293,030
| Country | Patent Number | Publication Date |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2017149199 | Sep 08, 2017 |
| United States of America | 2017246254 | Aug 31, 2017 |
| South Korea | 20180114018 | Oct 17, 2018 |
| Japan | 2019513123 | May 23, 2019 |
| >Country | >Patent Number | >Publication Date |
